Anledningen tilla att EMEA röstat emot har tydligen berott på ett
"ordmissföstånd":shock:
EpiCept did not seek marketing authorization for the treatment of malignant melanoma. We are seeking approval only for AML. Maxim Pharmaceuticals, whom we acquired in 2006, tested Ceplene in melanoma several years ago but was unsuccessful. The melanoma data was not part of our package submitted to the EMEA, and we were disappointed that this unrelated data became a reason for the negative trend vote.
Bob Cook
EpiCept Corporation
I can see a difference between the word "became" a reason or if he would have said "was" the reason. Are there more negative things which we haven`t heard about yet?
If not this must be the biggest joke ever if Ceplene won´t have an approval in march by EMEA.